Investors & media

Pure Biologics is a Polish biopharmaceutical company operating in the area of modern biological drugs. On the market since 2010, it was first in Poland to focus on developing new and innovative therapeutic molecules, not simply generic or biosimilar, based on antibodies and aptamers to be used in immuno-oncology and rare diseases applications.

In 2018, Pure Biologics entered the NewConnect market , and in 2020 transferred to the Main Market of the Warsaw Stock Exchange (as PURE).

Our team combines the recruitment of talent from renowned research groups, know-how acquired from years of activity, and an effective operating model, to drive the evolution of our own internal research projects, belonging to the most promising sectors of pharmaceutics.

Sources of funding for our therapeutic portfolio include grants from the European Union, complemented with revenue from contracted research delivered for pharmaceutical and biotechnology companies, as well as the capital invested by our company shareholders. The long-term strategy includes the partial reinvestment of profits from commercialization of our portfolio into our R&D activities and further development of the research program.

Shareholders

8,30%
276117 shares
Filip Jelen
President of the Board
5,70%
189720 shares
Augebit FIZ
86,00%
2861974 shares
Other shareholders
8,30%
276117 votes
Filip Jelen
President of the Board
5,70%
189720 votes
Augebit FIZ
86,00%
2861974 votes
Other shareholders
Share and votes table
Shareholder % shares % votes
Filip Jelen 8,30 8,30
Augebit FIZ 5,70 5,70
Other shareholders 86,00 86,00

Calendar of events and reports

15 IV
2023
Beginning of closed period before the announcement of quarterly financial report
15 V
2023
Q1 2023 periodic financial report
16 VIII
2023
Beginning of closed period before the announcement of half-yearly financial report
31 VIII
2023
HY1 2023 periodic financial report
16 X
2023
Beginning of closed period before the announcement of quarterly financial report
15 XI
2023
Q3 2023 periodic financial report
19 II
2024
Extraordinary General Meeting
18 III
2024
Extraordinary General Meeting
Today
27 III
2024
Extraordinary General Meeting
31 III
2024
Beginning of closed period before the announcement of annual financial report
15 IV
2024
Beginning of closed period before the announcement of quarterly financial report
30 IV
2024
2023 annual financial report
15 V
2024
Q1 2024 periodic financial report
17 VIII
2024
Beginning of closed period before the announcement of half-yearly financial report
16 IX
2024
HY1 2024 periodic financial report
16 X
2024
Beginning of closed period before the announcement of quarterly financial report
15 XI
2024
Q3 2024 periodic financial report

Download

Memoranda and prospectuses (PL)

Documents prepared in connection with the application for the introduction of financial instruments to trading conducted by the Warsaw Stock Exchange S.A.

Contact for investors

Martyna Koj

Director of the Company Office
Investor Relations Representative

Address for submitting notifications

According to Art. 19 of the Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (MAR)

Menu Close

We use cookies to give you the best browsing experience, site traffic analysis, and advertisement management.

Pure Biologics - Harnessing the power of antibodies and aptamers